Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLL2-BAAG in relapsed/refractory chronic lymphocytic leukemia
2017-003133-28Phase 2Completed
- Sponsor
- University of Cologne
- Start
- Aug 2018
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bendamustine, obinutuzumab, acalabrutinib and venetoclax in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by University of Cologne. Primary endpoint: Minimal residual disease negativity rate in peripheral blood. Started Aug 2018; status: completed.
02
Drugs
bendamustineobinutuzumabacalabrutinibvenetoclax
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2017-003133-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003133-28.